76.88
0.74%
-0.57
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio-Techne Corp stock is currently priced at $76.88, with a 24-hour trading volume of 524.39K.
It has seen a -0.74% decreased in the last 24 hours and a -6.21% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $77.67 pivot point. If it approaches the $76.35 support level, significant changes may occur.
Previous Close:
$77.45
Open:
$77.12
24h Volume:
524.39K
Market Cap:
$12.12B
Revenue:
$1.15B
Net Income/Loss:
$203.00M
P/E Ratio:
50.58
EPS:
1.52
Net Cash Flow:
$251.15M
1W Performance:
-2.47%
1M Performance:
-6.21%
6M Performance:
+3.89%
1Y Performance:
+0.20%
Bio-Techne Corp Stock (TECH) Company Profile
Name
Bio-Techne Corp
Sector
Industry
Phone
612-379-8854
Address
614 McKinley Place NE, Minneapolis, MN
Bio-Techne Corp Stock (TECH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
Feb-02-24 | Downgrade | Stifel | Buy → Hold |
Dec-07-23 | Initiated | UBS | Buy |
Aug-28-23 | Initiated | William Blair | Outperform |
Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
Feb-23-21 | Upgrade | Stifel | Hold → Buy |
Jan-25-21 | Reiterated | The Benchmark Company | Buy |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
May-27-20 | Downgrade | Stifel | Buy → Hold |
May-14-20 | Initiated | The Benchmark Company | Buy |
Jan-08-20 | Resumed | Stephens | Overweight |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Neutral |
Nov-15-19 | Initiated | Stifel | Buy |
Jul-02-19 | Upgrade | Janney | Neutral → Buy |
Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
Oct-17-18 | Initiated | Goldman | Neutral |
Jun-15-18 | Initiated | Argus | Buy |
Jul-13-17 | Initiated | Wells Fargo | Market Perform |
Feb-09-17 | Initiated | Citigroup | Buy |
Jan-18-17 | Initiated | Deutsche Bank | Buy |
Nov-10-16 | Resumed | Leerink Partners | Outperform |
Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio-Techne Corp Stock (TECH) Latest News
10,000 Shares in Bio-Techne Co. (NASDAQ:TECH) Purchased by Harbert Fund Advisors Inc. - MarketBeat
MarketBeat
3 High-Quality Small-Cap Stocks That Investors Are Overlooking - The Globe and Mail
The Globe and Mail
3 High-Quality Small-Cap Stocks That Investors Are Overlooking - TradingView
TradingView
Brown Capital Management LLC Has $273.99 Million Position in Bio-Techne Co. (NASDAQ:TECH) - Defense World
Defense World
Mairs & Power Inc. Has $237.61 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
MarketBeat
Icon Wealth Advisors LLC Makes New $606000 Investment in Bio-Techne Co. (NASDAQ:TECH) - Defense World
Defense World
Bio-Techne Corp Stock (TECH) Financials Data
Bio-Techne Corp (TECH) Revenue 2024
TECH reported a revenue (TTM) of $1.15 billion for the quarter ending March 31, 2024, a +2.73% rise year-over-year.
Bio-Techne Corp (TECH) Net Income 2024
TECH net income (TTM) was $203.00 million for the quarter ending March 31, 2024, a -25.18% decrease year-over-year.
Bio-Techne Corp (TECH) Cash Flow 2024
TECH recorded a free cash flow (TTM) of $251.15 million for the quarter ending March 31, 2024, a +7.91% increase year-over-year.
Bio-Techne Corp (TECH) Earnings per Share 2024
TECH earnings per share (TTM) was $1.26 for the quarter ending March 31, 2024, a -24.44% decline year-over-year.
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Cap:
|
Volume (24h):